Catalent, Inc. (0C8.F)

51,77 -0,61 (-1,16%) Al cierre: 08:04AM CEST

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 18.000

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. John J. Greisch M.B.A.	Executive Chairman of the Board	116,72k	N/A	1955
Mr. Alessandro Maselli	President, CEO & Director	1M	N/A	1972
Dr. Aristippos Gennadios Ph.D.	Group President of Pharma & Consumer Health Segment	740,95k	N/A	1966
Mr. Ricky Hopson	President, Division Head for BioProduct Delivery & Chief of Staff	576,74k	N/A	1977
Mr. Matti M. Masanovich	Senior VP & CFO	N/A	N/A	1972
Mr. Michael J. Hatzfeld Jr.	VP & Chief Accounting Officer	N/A	N/A	1973
Mr. Charles Lickfold	Senior VP & Chief Information Officer	N/A	N/A	1974
Mr. Paul Surdez	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Joseph A. Ferraro J.D.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	N/A	N/A	1978
Mr. Michael J. Grippo	Senior Vice President of Strategy & Corporate Development	N/A	N/A	1969

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Catalent, Inc., a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 10; Tablero: 8; Derechos de los accionistas: 6; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.